{"id":"W3119449300","doi":"10.1016/j.ccell.2020.12.017","title":"Lorlatinib in ALK-Rearranged Lung Cancer","year":2021,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer; Princess Margaret Cancer Foundation; Roche; Open Society Institute; Takeda Canada; Novartis","keywords":"Crizotinib; Lung cancer; Anaplastic lymphoma kinase; Medicine; Internal medicine; Oncology; ALK inhibitor; Interim analysis; Pemetrexed; Adenocarcinoma; Chemotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011613,0.000615569,0.0009054547,0.0005026385,0.002819525,0.002597097,0.0008075251,0.02396213,0.005461836],"category_scores_gemma":[0.007341902,0.0003500007,0.0008546558,0.0004499481,0.001207139,0.001610985,0.0007452832,0.01483897,0.003359756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004093741,"about_ca_system_score_gemma":0.003338525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007455359,"about_ca_topic_score_gemma":0.01690259,"domain_scores_codex":[0.9989877,0.0002990963,0.00009718321,0.00009428136,0.0003055873,0.0002160908],"domain_scores_gemma":[0.9986215,0.0007231864,0.00009802743,0.00003849404,0.0001888453,0.0003300768],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001874104,0.00009047763,0.001840678,0.00006564358,0.00002629012,0.007270245,0.0000828124,0.0003048412,0.0004736246,0.00451684,0.9598579,0.02528323],"study_design_scores_gemma":[0.0004054463,0.000302353,0.003564996,0.0004859747,0.0000827469,0.009869494,0.0003755569,0.003256191,0.0007907886,0.0169214,0.9638677,0.00007741769],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.002317844,0.002786287,0.0001331238,0.9610487,0.01532176,0.00002507389,0.0001362717,0.00003965622,0.01819132],"genre_scores_gemma":[0.02664026,0.003665216,0.0004895605,0.8816474,0.05194489,0.00006499854,0.000137026,0.0000442515,0.03536641],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02396213,"threshold_uncertainty_score":0.02970225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02150282214088282,"score_gpt":0.346329649892598,"score_spread":0.3248268277517151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}